Date: June 25, 2024 By: Nick Kolev
Ragon faculty member and Early Independence Fellow Charles Evavold, PhD, has been selected as the recipient of the prestigious 2024-2025 Karin Grunebaum Cancer Research Foundation Faculty Research Fellowship at Harvard Medical School. The fellowship selection committee was deeply impressed by Evavold’s accomplishments and his potential for leadership in cancer research.
Evavold was also invited to present his research at the semiannual meeting of the board of the Karin Grunebaum Cancer Research Foundation, which will be held at Boston University Medical Center on Friday, June 14.
Evavold is a Principal Investigator at the Ragon Institute and an Instructor at Harvard Medical School. His research focuses on synthetic immunity and cell death regulation, studying fundamental cellular decision-making using cell death programs as a model system. His lab aims to uncover novel regulation in these processes, combining genomic or chemical perturbations with synthetic biology models.
The Karin Grunebaum Cancer Research Foundation is dedicated to advancing cancer research and supporting scientists who show exceptional promise in this vital area of medical science.
Congratulations, Dr. Evavold!
Researchers at the Ragon Institute of Mass General Brigham, MIT, and Harvard have uncovered critical insights into how aging impairs the immune system’s ability to fight cancer.
This study, published in Immunity on August 30, used a non-human primate model to demonstrate that previous Mtb infection leads to a durable, protective immune response that is dependent on CD4+ T cells.
MIT researchers find that the first dose primes the immune system, helping it to generate a strong response to the second dose, a week later.